Company profile

Ticker
BMY, BMY-RI, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
220790350

BMY stock data

(
)

Calendar

5 Nov 20
5 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
2 Dec 20 Rupert Vessey Common Stock, $0.10 par value Payment of exercise Dispose F No 62.18 4,506 280.18K 42,208
2 Dec 20 Rupert Vessey Common Stock, $0.10 par value Option exercise Aquire M No 0 8,792 0 46,714
2 Dec 20 Rupert Vessey RSU Common Stock, $0.10 par value Option exercise Dispose M No 0 8,792 0 26,376
2 Dec 20 Nadim Ahmed Common Stock, $0.10 par value Payment of exercise Dispose F No 62.18 3,380 210.17K 31,603
2 Dec 20 Nadim Ahmed Common Stock, $0.10 par value Option exercise Aquire M No 0 6,594 0 34,983
2 Dec 20 Nadim Ahmed RSU Common Stock, $0.10 par value Option exercise Dispose M No 0 6,594 0 19,782
2 Dec 20 David V Elkins Common Stock, $0.10 par value Payment of exercise Dispose F No 62.18 5,087 316.31K 58,487
2 Dec 20 David V Elkins Common Stock, $0.10 par value Option exercise Aquire M No 0 8,792 0 63,574
2 Dec 20 David V Elkins RSU Common Stock, $0.10 par value Option exercise Dispose M No 0 8,792 0 26,376
2 Dec 20 Boerner Christopher S. Common Stock, $0.10 par value Payment of exercise Dispose F No 62.18 1,299 80.77K 22,371
72.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2133 2210 -3.5%
Opened positions 126 150 -16.0%
Closed positions 203 121 +67.8%
Increased positions 703 935 -24.8%
Reduced positions 1080 851 +26.9%
13F shares
Current Prev Q Change
Total value 994.11B 947.68B +4.9%
Total shares 1.64B 2.17B -24.7%
Total puts 20.74M 24.38M -15.0%
Total calls 19.03M 28.94M -34.3%
Total put/call ratio 1.1 0.8 +29.4%
Largest owners
Shares Value Change
Vanguard 200.07M $12.06B -1.9%
BLK Blackrock 162.41M $9.79B -2.0%
STT State Street 97.49M $5.88B -1.6%
JPM JPMorgan Chase & Co. 66.36M $3.98B -12.6%
FMR 62.63M $3.78B -13.0%
Wellington Management 53.99M $3.25B -15.2%
Geode Capital Management 33.73M $2.03B +2.1%
BAC Bank Of America 32.89M $1.98B -4.7%
Renaissance Technologies 30.58M $1.84B -38.3%
BRK.A Berkshire Hathaway Inc. - 29.97M $1.81B NEW
Largest transactions
Shares Bought/sold Change
Pentwater Capital Management 0 -53.54M EXIT
Laurion Capital Management 555.19K -48.02M -98.9%
Farallon Capital Management 3.75M -44.08M -92.2%
BRK.A Berkshire Hathaway Inc. - 29.97M +29.97M NEW
Abrams Capital Management 0 -23.2M EXIT
CS Credit Suisse 5.28M -19.37M -78.6%
Renaissance Technologies 30.58M -18.97M -38.3%
Viking Global Investors 3.19M -15.78M -83.2%
JHG Janus Henderson 23.74M -14.44M -37.8%
GS Goldman Sachs 8.59M -13.01M -60.2%

Financial report summary

?
Risks
  • The COVID-19 pandemic is affecting our business and could have a material adverse effect on us.
  • It is possible that the COVID-19 pandemic could delay the timing of the FDA’s approval decisions for liso-cel and ide-cel, which could have a material adverse effect on the CVRs that we issued in connection with the Celgene transaction.
  • U.S. executive orders on biopharmaceutical pricing and other potential initiatives by the U.S. federal government to implement measures to regulate drug pricing in the future could adversely affect our business.
Management Discussion
  • (a)    Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
  • (b)    Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
  • •U.S. revenues for the third quarter 2020 and year-to-date were impacted by Revlimid and other Celgene products ($3.0 billion and $8.8 billion, respectively), which contributed 88% and 83%, respectively, of the growth. Average net selling prices decreased 1% in the third quarter 2020 and increased 2% year-to-date.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adenocarcinoma, aprpoved, Area, banc, BCBSA, BCBSM, bevacizumab, Blue, BSC, candidate, carcinoma, cardiomyopathy, clear, conventional, curative, cytarabine, cytokine, DAYBREAK, deucravacitinib, DNA, Dragonfly, driven, durable, electronic, en, epidermal, fibrotic, gastroesophageal, HCSC, hypertrophic, identification, IDHENTIFY, Idhifa, incidence, infection, inspection, instability, intensive, invented, IRS, isocitrate, junction, Korea, lab, link, lowest, mavacamten, microsatellite, MyoKardia, neuroinflammation, obstructive, occurrence, Onureg, Organisation, PASI, pathologic, percent, petition, plaque, POETYK, political, quantity, reconsider, RNA, rulemaking, SCLC, score, Secretary, sensitizing, Shield, sNDA, South, sPGA, static, sued, surgery, Taiwan, translocation, unlimited, unspecified, unused, urothelial, withdrawn
Removed: analgesic, cellular, concomitantly, designation, Gulf, medication, objective, Perfalgan, updated